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Purpose of the study
To further investigate CPK increases and muscle symp-
toms in a cohort of HIV-infected patients receiving ral-
tegravir-based HAART compared with a control cohort
with similar characteristics receiving darunavir-based
HAART.
Methods
T h eS C O L T AP r o j e c ti sap r o s p ective, observational,
multicenter study created toa s s e s st h ei n c i d e n c eo f
adverse events in patients receiving new antiretroviral
drugs in clinical practice. Muscle symptoms where clas-
sified according to the American Heart Association
guidelines and CPK elevations were graded according to
the DAIDS table.
Results
A total of 391 HIV-infected patients were included in
the study, 258 (66.0%) males. CDC stage was C in 152
(38.9%) patients. Mean age at enrolment was 44.5 ± 9.0
years, mean CD4 cell count 348 ± 260 cell/µL and mean
HIV-RNA 3.26 ± 1.54 log10 cp/ml; 135 (35.2%) patients
were HCV Ab+ and 155 (39.6%) had a diagnosis of lipo-
dystrophy. Sixteen (4.1%) were naive to antiretrovirals.
No statistical difference was observed regarding baseline
characteristics when comparing patients receiving ralte-
gravir (n=293) and darunavir-based HAART (n=98).
Thirteen patients (5.4%) receiving raltegravir referred
muscle pain and 12 (5.0%) muscle weakness compared
with 1 (1.1%) and 0 (0%) receiving darunavir (p=0.20
and p=0.04), respectively. Seventeen (5.8%) patients
developed muscle pain and/or weakness in the raltegra-
vir cohort in respect of 1 (1.0%) in the darunavir cohort
(p=0.05). No statistical difference was observed when
considering CPK increases (>200 U/L) that were
reported in 26 (8.9%) patients treated with raltegravir
and 11 (11.2%) receiving darunavir. No relation emerged
between CPK increase and muscle pain/weakness. Of
note, no patient discontinued raltegravir due to CPK
elevations or worsening muscle symptoms and no cases
of rhabdomyolysis were reported.
Conclusions
CPK elevations occurred in >10% of patients receiving
both raltegravir and darunavir suggesting a multifactor-
ial aetiology in HIV-infected patients treated with
HAART. Raltegravir-treated patients had a significantly
higher proportion of muscle symptoms, especially mus-
cle weakness. However, these symptoms did not cause
therapy discontinuation, in our cases. Although the lim-
ited clinical significance to date, our data suggest the
monitoring of muscle symptoms, including both pain
and weakness, in patients receiving raltegravir and
further diagnostic evaluations if they persist.
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